# Study of Tocilizumab in Combination With Methotrexate for Treatment of Moderate to Severe Rheumatoid Arthritis Patients

> **NCT01258712** · PHASE3 · COMPLETED · sponsor: **Chugai Pharma Taiwan** · enrollment: 86 (actual)

## Conditions studied

- Rheumatoid Arthritis (RA)

## Interventions

- **DRUG:** Tocilizumab + methotrexate(MTX)
- **DRUG:** Tocilizumab placebo + methotrexate(MTX)

## Key facts

- **NCT ID:** NCT01258712
- **Lead sponsor:** Chugai Pharma Taiwan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2012-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01258712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01258712, "Study of Tocilizumab in Combination With Methotrexate for Treatment of Moderate to Severe Rheumatoid Arthritis Patients". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01258712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*